Cancer incidence in patients with polyglutamine diseases: a population-based study in Sweden.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Lancet Oncology

• Publication date

  2012-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(12)70132-8PMID 22503213
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The hallmarks of cancer

  2012cited by this paper
• Substance abuse may be a risk factor for earlier onset of Huntington disease

  2012cited by this paper
• No paradox, no progress: inverse cancer comorbidity in people with other complex diseases.

  2011cited by this paper
• p53 and its mutants in tumor cell migration and invasion

  2011cited by this paper
• External review and validation of the Swedish national inpatient register

  2011cited by this paper
• Update on degenerative ataxias.

  2011cited by this paper
• Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond.

  2010cited by this paper
• Cancer and Neurodegeneration: Between the Devil and the Deep Blue Sea

  2010cited by this paper
• What are the hallmarks of cancer?

  2010cited by this paper
• The first 30 years of p53: growing ever more complex

  2009cited by this paper
• Is cancer triggered by altered signalling of nicotinic acetylcholine receptors?

  2009cited by this paper
• Polyglutamine diseases: emerging concepts in pathogenesis and therapy.

  2007cited by this paper
• Huntington disease as a dual diagnosis disorder: data from the National Research Roster for Huntington disease patients and families.

  2007cited by this paper
• Huntington's disease.

  2007cited by this paper
• Monozygotic twins discordant for Huntington disease after 7 years.

  2005cited by this paper
• Diseases of Unstable Repeat Expansion: Mechanisms and Common Principles

  2005cited by this paper
• p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease.

  2005cited by this paper
• Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders.

  2002cited by this paper
• Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor.

  2002cited by this paper
• Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis

  2001cited by this paper
• Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity

  2001cited by this paper
• The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

  2000cited by this paper
• Polyglutamine disease and neuronal cell death.

  2000cited by this paper
• Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease

  1999cited by this paper
• Significantly lower incidence of cancer among patients with Huntington disease

  1999cited by this paper
• Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates

  1998cited by this paper
• Statistical methods in cancer research. Volume IV. Descriptive epidemiology.

  1998cited by this paper
• Huntington's disease.

  1997cited by this paper
• Spinal and bulbar muscular atrophy: androgen receptor dysfunction caused by a trinucleotide repeat expansion.

  1996cited by this paper
• Abnormal androgen receptor binding affinity in subjects with Kennedy's disease (spinal and bulbar muscular atrophy).

  1995cited by this paper
• Trinucleotide repeat length instability and age of onset in Huntington's disease

  1993cited by this paper
• Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease

  1993cited by this paper
• The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

  1993cited by this paper
• Moderate instability of the trinucleotide repeat in spino bulbar muscular atrophy.

  1992cited by this paper
• Statistical methods in cancer research. Volume II--The design and analysis of cohort studies.

  1987cited by this paper
• [Modern epidemiology].

  1971cited by this paper

• Lifetime risk of cancer in carriers of intermediate alleles in the HTT gene

  2026cites this paper
• HTT, ATXN1 and ATXN2 CAG triplet repeat sizes: exploring their role in the disease risk and cancer comorbidity in Parkinson’s disease

  2025cites this paper
• Early life functional advantage coupled with accelerated aging: The case for antagonistic pleiotropy in Huntington's disease.

  2025cites this paper
• Disease–disease interactions: molecular links of neurodegenerative diseases with cancer, viral infections, and type 2 diabetes

  2025cites this paper
• A novel non-negative Bayesian stacking modeling method for Cancer survival prediction using high-dimensional omics data

  2024cites this paper
• Update: Protective and risk factors for Parkinson disease.

  2024cites this paper
• Apoptosis Genes as a Key to Identification of Inverse Comorbidity of Huntington’s Disease and Cancer

  2023cites this paper
• Upregulated Chaperone-Mediated Autophagy May Perform a Key Role in Reduced Cancer Incidence in Huntington’s Disease

  2023cites this paper
• Incidence and prevalence of Spinal and bulbar muscular atrophy in South Korea: a nationwide population-based study

  2023cites this paper
• TRIM family proteins: roles in proteostasis and neurodegenerative diseases

  2022cites this paper
• Huntingtin Overexpression Does Not Alter Overall Survival in Murine Cancer Models

  2022cites this paper
• Comorbidities and clinical outcomes in adult- and juvenile-onset Huntington’s disease: a study of linked Swedish National Registries (2002–2019)

  2022cites this paper
• The BAFfling story of MN1-induced leukemogenesis.

  2021cites this paper
• Alzheimer's disease, Huntington's disease and cancer.

  2021cites this paper
• Selective forces acting on spinocerebellar ataxia type 3/Machado–Joseph disease recurrency: A systematic review and meta‐analysis

  2020cites this paper
• The Inverse Comorbidity between Oncological Diseases and Huntington’s Disease: Review of Epidemiological and Biological Evidence

  2020cites this paper
• Proteostasis and Disease: From Basic Mechanisms to Clinics

  2020cites this paper
• Machado-Joseph Disease: A Stress Combating Deubiquitylating Enzyme Changing Sides.

  2020cites this paper
• Polyglutamine protein in tumor cells sensitizes tumor cells to natural killer cell cytolysis.

  2020cites this paper
• Drugging DNA Damage Repair Pathways for Trinucleotide Repeat Expansion Diseases

  2020cites this paper
• Meta‐analysis of the Correlation Between Schizophrenia and Breast Cancer

  2019cites this paper
• Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis

  2019cites this paper
• CRMP5-associated GTPase (CRAG) Is a Candidate Driver Gene for Colorectal Cancer Carcinogenesis

  2019cites this paper
• Reduced Cancer Incidence in Huntington’s Disease: Analysis in the Registry Study

  2018cites this paper
• Hippo Signaling Pathway Dysregulation in Human Huntington’s Disease Brain and Neuronal Stem Cells

  2018cites this paper
• Cancer: From Wild-Type to Mutant Huntingtin

  2018influential citation
• Small interfering RNAs based on huntingtin trinucleotide repeats are highly toxic to cancer cells

  2018cites this paper
• The central role of DNA damage and repair in CAG repeat diseases

  2018influential citation
• Trinucleotide Repeat Expansion Diseases, RNAi, and Cancer.

  2018cites this paper
• Cancer in Machado-Joseph disease patients-low frequency as a cause of death.

  2017cites this paper
• Enhanced Degradation of Misfolded Proteins Promotes Tumorigenesis.

  2017cites this paper
• Monogenic Diseases of DNA Repair

  2017cites this paper
• Augmented capacity to clear misfolded proteins: An intrinsic characteristic of tumor cells?

  2017cites this paper
• Cancer and neurodegeneration

  2017cites this paper
• Low cancer prevalence in polyglutamine expansion diseases

  2017cites this paper
• CAG repeat size in Huntingtin alleles is associated with cancer prognosis

  2016cites this paper
• [Beyond the brain: huntingtin in breast cancers].

  2016cites this paper
• Cancer risk and mortality in asthma patients: A Swedish national cohort study

  2015cites this paper
• Diametrical diseases reflect evolutionary-genetic tradeoffs

  2015cites this paper
• Reduced Risk of Cancer in Schizophrenia, a Bridge Toward Etio-Pathology and Therapy of Both Diseases

  2015cites this paper
• Curation of the Mammalian Palmitoylome Indicates a Pivotal Role for Palmitoylation in Diseases and Disorders of the Nervous System and Cancers

  2015cites this paper
• Corticostriatal synaptic adaptations in Huntington’s disease

  2015cites this paper
• Survival and severity in dominant cerebellar ataxias

  2015cites this paper
• Contribution of shared environmental factors to familial aggregation of common cancers: an adoption study in Sweden.

  2015cites this paper
• Treating the whole body in Huntington's disease.

  2015cites this paper
• Altered mTOR signaling in Huntington's Disease

  2015cites this paper
• HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation

  2015cites this paper
• Pleomorphic Invasive Ductal Carcinoma of the Breast in a Patient with Huntington's Disease

  2014cites this paper
• p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin.

  2014cites this paper
• Impaired striatal function in Huntington's disease is due to aberrant p75NTR signaling

  2014cites this paper
• Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50 Observational Studies

  2014influential citation
• Au-delà du cerveau : une importance majeure de la huntingtine et de sa phosphorylation à la sérine 421 dans les cancers du sein

  2014cites this paper
• Clinical, demographic, and pharmacologic features of nursing home residents with Huntington's disease.

  2014cites this paper
• Drosophila Myc, a novel modifier suppresses the poly(Q) toxicity by modulating the level of CREB binding protein and histone acetylation.

  2014influential citation
• Surveying the Landscape of Huntington's Disease Mechanisms, Measurements, and Medicines

  2013cites this paper
• Life Without Hope? Huntington's Disease and Genetic Futurity

  2013cites this paper
• Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.

  2013cites this paper
• Life without Hope

  2013cites this paper
• Reduced cancer incidence in Huntington's disease: record linkage study clue to an evolutionary trade‐off?

  2013influential citation
• Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders

  2013cites this paper
• The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling

  2013cites this paper
• Huntingtin: Here, There, Everywhere!

  2013cites this paper
• 特別講演 Academic Knowledge Centers (AKCs) : a unique concept in Swedish primary care (第61回日本農村医学会総会特集)

  2013cites this paper
• Genetics: Polyglutamine repeats or cancer?

  2012cites this paper
• Polyglutamine diseases and the risk of cancer.

  2012cites this paper
• The Huntington disease protein accelerates breast tumor development and metastasis through ErbB 2 / HER 2 signalling

  2012influential citation
• miRNAs have prognostic signifi cance in various haematological and solid tumours. In The Lancet Oncology, Liu and colleagues

  2012cites this paper
• The role of the cofilin-actin rod stress response in neurodegenerative diseases uncovers potential new drug targets

  2012cites this paper
• NEUROLOGY AND PRECLINICAL NEUROLOGICAL STUDIES - REVIEW ARTICLE

  year unknowncites this paper